Skip Navigation
Search Menu

Print This Page
Share this page: More

Search Results

A Phase II Trial of Hippocampal-Sparing Prophylactic Cranial Irradiation (PCI) for Small Cell Lung Cancer (SCLC)
Protocol Number:
Phase II
Kristin Redmond
Johns Hopkins Kimmel Cancer Center in Baltimore
Johns Hopkins Bayview Medical Center
This research is being done to see if decreasing radiation exposure to a certain area of the brain called the hippocampus will decrease side effects from radiation to the brain (prophylactic cranial irradiation) such as short term memory loss compared to standard radiation to the brain.
Inclusion Criteria: * Histological or cytological evidence of Small Cell Lung Cancer * Performance status of less than or equal to to 1 * Limited stage disease with complete response to chemotherapy and chest irradiation confimrmed by at least a chest x-ray within on month of study entry * Negative CT or MRI of the brain within one month of study entry * Women of child-bearing potential must have a negative pregnancy test and agree to the use of adequate contraception before starting on the protocol * Must be able to understand and sign the study's informed consent document Exclusion Criteria: *Evidence of brain metastases and/or ipsilateral lung metastases/malignant plural effusion *Prior malignancy within the past five years other than nonmelanomatous skin cancer or carcinoma in situ of the cervix * Patients with epilepsy requiring permanent oral medication * Patients may not take Memantine * Pregnant or breastfeeding
* Have testing on your memory and thinking before you start radiation treatment * Have two weeks of radiation to the whole brain
Last Update
09/27/2016 05:03 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.